Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19

Alexandre Naime Barbosa, Antonio Silvinato, Hélio Bacha, Idevaldo Floriano, Suzana Tanni, Wanderley Bernardo

Open source

DOI: 10.1590/1806-9282.2022d681
Published: 2022-01
Container: Revista da Associação Médica Brasileira
Publisher: FapUNIFESP (SciELO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1590/1806-9282.2022d681,
  title = {Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19},
  author = {Alexandre Naime Barbosa and Antonio Silvinato and Hélio Bacha and Idevaldo Floriano and Suzana Tanni and Wanderley Bernardo},
  year = {2022},
  journal = {Revista da Associação Médica Brasileira},
  doi = {10.1590/1806-9282.2022d681},
  url = {https://doi.org/10.1590/1806-9282.2022d681}
}

RIS

TY  - JOUR
TI  - Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19
AU  - Alexandre Naime Barbosa
AU  - Antonio Silvinato
AU  - Hélio Bacha
AU  - Idevaldo Floriano
AU  - Suzana Tanni
AU  - Wanderley Bernardo
PY  - 2022
JO  - Revista da Associação Médica Brasileira
DO  - 10.1590/1806-9282.2022d681
UR  - https://doi.org/10.1590/1806-9282.2022d681
ER  -

APA

Barbosa, A. N., Silvinato, A., Bacha, H., Floriano, I., Tanni, S., & Bernardo, W. (2022). Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19. Revista da Associação Médica Brasileira. https://doi.org/10.1590/1806-9282.2022d681

Source records

crossref · retrieved 2026-09-27T03:12:52.008Z